Menu
ncarol.com
  • Home
  • Business
  • Health
  • Arts
  • Education
  • Technology
  • Real Estate
  • Books
  • Non-profit
ncarol.com

Bryn Pharma Announces Expansion of Leadership Team as UTULY™ Investigative Needle-Free Epinephrine Nasal Spray Prepares for Market Entry
ncarol.com/10229602

Trending...
  • xREnergy up as much as +3,094,634% on first day listed on the XRP Ledger. Ticker : $XRE
  • Green Energy Solar Expands with New Offices in Port St. Lucie, West Palm Beach, and Orlando
  • Bonelli Systems Expands Managed IT Services Nationwide, Leveraging Microsoft Azure Expertise
RALEIGH, N.C.--(BUSINESS WIRE)--Bryn Pharma, LLC, a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, announced today that it has expanded its leadership team as the company further prepares for the market entry of UTULY™, an investigational self-administered form of epinephrine being studied for the treatment of type 1 allergic reactions, including anaphylaxis. The new hires include: Jeff Evans, Head of Manufacturing Operations; Dr. Karen Rance, Head of Medical Affairs; Jeremy Shepler, Head of Sales and Marketing; and, Brian Tabakin, Head of Market Access.

"The addition of Jeff, Karen, Jeremy, and Brian represents a significant step forward in Bryn's progress toward commercialization as we prepare to bring our much-needed and innovative therapy to market," said CEO Sandy Loreaux. "We have diligently built a stellar team of seasoned executives over the past several months, each contributing perfectly aligned skill sets and deep experience in the healthcare and anaphylaxis space to ensure a successful launch and market entry of UTULY. We are thrilled that they are on board and embrace our commitment to offering people with anaphylaxis an affordable, needle-free epinephrine nasal spray that is also convenient and has rapid uptake of epinephrine."

Jeremy Shepler serves as Head of Sales and Marketing for Bryn, where he is responsible for building Bryn's sales force and overall brand strategy and tactical execution. For the past two decades, Jeremy has held various commercial roles in the pharmaceutical/biotech industry. In his most recent role, Jeremy served as Vice President, Area Commercial Lead, Cardiometabolic Sales for the East Area at Novo Nordisk, where he has held roles of increasing responsibility since 2010. He also served as Vice President, Injectable GLP-1 Marketing, a journey that began in 2015 when he was promoted to lead the commercialization of Ozempic.® He was responsible for the early commercialization plan for the blockbuster that would become Ozempic, co-chairing the Global Project Team to architect the forthcoming launch and lifecycle management plan. That planning led to the first-ever agile/phased launch approach in the industry, which has since been adopted by Novo Nordisk and across the industry. Now, Ozempic is an established household brand, on its way to septuple blockbuster ($7B) status. Jeremy has deep sales and marketing experience in other pharmaceutical organizations, such as Meda, Accentia, and InVentiv Health, US. Jeremy earned a BS from Bentley University and is a recent participant in the Wharton School of Business Executive Leadership Program.

More on ncarol.com
  • Aureli Construction Sets the Standard for Seamless Home Additions in Greater Boston
  • ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
  • Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
  • Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
  • Robert Fabbio Inducted into the Austin Technology Council Hall of Fame

Brian Tabakin serves as Bryn's Head of Market Access, where he oversees all aspects of market access including direct customer-facing account teams for payers, PBMs, specialty and retail pharmacies, GPOs, wholesalers, and distributors. He is responsible for developing pricing, access, contracting, and channel distribution strategies. Prior to joining Bryn, Brian was Vice President, Head of Market Access for Sunovion Pharmaceuticals, where he led the development and execution of high-return strategies. In his most recent role, Brian led a 135-person Market Access team with a focus on creating access for therapies across multiple disease areas. Prior to Sunovion, Brian was with Sanofi. He enjoys using his analytical and creative skills to rethink market approaches with the goal of consistently driving access profitability. Brian earned his BBA in Finance and Business Logistics from Penn State University and was a participant in the Babson Executive Leadership Program.

Dr. Karen Rance, DNP, CPNP, serves as Head of Medical Affairs for Bryn, where she oversees medical education and relationships with the patient and professional anaphylaxis communities on behalf of Bryn. She trained and previously practiced as an allergy, asthma, and immunology specialty NP. Most recently, Karen served as the North American Head of Medical Affairs for ALK Abello, a Global Pharmaceutical company specializing in Allergy Immunotherapy. In addition to this position, she led industry leaders as the Industry Chair of the Allergy College of Allergy, Asthma, and Immunology (ACAAI) Corporate Council. She received the National Medical Science Liaison Society's top award and national recognition for leading her Medical Science Liaison team. While in practice, she served on the National Institutes of Health's National Asthma Education and Prevention Program workgroup and the National Association of Pediatric Nurse Practitioners​ (NAPNAP) Asthma Clinical Expert Panel. She is the Founding Chair of the NAPNAP's Asthma and Allergy Special Interest Group. She served on the Board of Directors of the National Asthma Education Certification Board, as President of the Indiana Joint Asthma Coalition, and on the Allied Health Leadership Council of the American College of Allergy, Asthma, and Immunology. She regularly presented at National and State Allergy conferences throughout her years in practice, including the American Academy of Allergy, Asthma, and Immunology (AAAAI) and the American College of Asthma Allergy and Immunology (ACAAI). Karen earned her Doctorate in Nursing Practice from the University of Virginia.

More on ncarol.com
  • Cybersecurity is Protecting Your Personal Information and Your Portfolio
  • Matthew Glova, CFP® of LifeTime Asset Honored in Forbes Best-In-State Wealth Advisors2025
  • L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
  • Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
  • Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs

Jeff Evans serves as the Head of Manufacturing Operations, where he oversees all aspects of manufacturing and ensures that all product quality standards are met. He has over 18 years of healthcare medical device experience. Prior to joining Bryn, Jeff held a variety of leadership positions at Johnson & Johnson Vision Care in Supply Chain, Project Management, and R&D. In his most recent role, Jeff led a 130-person R&D New Product Introduction team to develop and deliver clearly defined manufacturing requirements, robust manufacturing processes, and high-quality products with world-class technology transfer. A key theme throughout his assignments has been leading cross-functional teams to deliver new product innovation. Throughout his career, Jeff has been involved in multiple launches, including combination drug-device products and the first combination product contact lens. Prior to Johnson & Johnson, Jeff had assignments with General Electric Transportation Systems and was a founding member of a startup business in Homeland Security Consulting with TRC Companies, Inc. After graduating from the United States Military Academy with a degree in mechanical engineering, Jeff served as an infantry officer for eight years. Jeff is a certified Six Sigma Master Black Belt.

About Bryn Pharma

Bryn Pharma, established in 2017, is a privately held pharmaceutical company founded by patients for patients. Bryn is focused on positively disrupting the existing market for epinephrine autoinjectors by delivering an accessible, easy-to-use alternative that better meets the needs of patients. Bryn Pharma seeks to provide this growing population at risk for anaphylaxis with A Better Way to be prepared for a life-threatening allergic reaction. For more information visit www.brynpharma.com.

Contacts

Rebecca Novak Tibbitt
Rebecca@RNTCommunications.com
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Congressional Men's Health Caucus Shows Bipartisan Consensus and Focus on Prevention, Mental Health, and Closing the Lifespan Gap
  • DuoKey, Axiomtek and Blue Edge Network Partner to Enhance Smart Cities with Privacy-Preserving Urban Safeguarding and Fleet Management
  • Costa Oil Racing and Rick Ware Racing Celebrate Back-to-Back Victories Across the Country
  • Austin Keen Joins WakeFX RopePal as Official Brand Ambassador
  • Bonelli Systems Expands Managed IT Services Nationwide, Leveraging Microsoft Azure Expertise
  • $4.3 Million Patent Application Waiver Fee Granted by FDA on New Drug Application Fee for Treatment Addressing Suicidal Depression & PTSD: NRX Pharma
  • Whistleblower Claims Dental Patient Deaths Likely Due to Book Ban
  • Dr. Michael Matzinger Honored with Silver Antelope Award for Distinguished Service to Youth
  • xREnergy up as much as +3,094,634% on first day listed on the XRP Ledger. Ticker : $XRE
  • Psychiatry's Legacy of Racism and Coercion Highlighted in Restraint Deaths
  • New Book 'Cybersecurity Leadership' Guides SME Leaders to Make Smart, Strategic Security Decisions
  • Longtime Durham Bulls Performer and Dog Trainer Hit Hard by Economic Shift
  • "Stop scrolling and start watching" - Beloved film recommendation site Criticker gets a major makeover
  • Green Energy Solar Expands with New Offices in Port St. Lucie, West Palm Beach, and Orlando
  • Introducing the Wackadoodles for Kids Music
  • Events by Dubsdread Expands Services to The Venue at Lake Lily
  • London Gala Emphasizes Trade, FDI and Ongoing Cooperation
  • Sahit Muja Launches Trillion-Dollar Green Revolution with 10 Groundbreaking Cryptos
  • Free and Low-Cost Dental Care Now Available in London Through the Canadian Dental Care Plan (CDCP)
  • Garden State Gay Socials Turns One: 1st Birthday Celebration for Gay Men Who Want Real Connection
_catLbl0 _catLbl1

Popular on ncarol.com

  • Village Vapes and Cooking 4 Autism Announce Inaugural Partnership at MEGA 420 EVENT - 174
  • Perfect Body Laser & Aesthetics Launches New Website - 127
  • North American Security Launches New Website to Reflect Evolving Industry Demands and Client-Centered Solutions - 102
  • The World's No.1 Superstar Champions the NO FAKES Act – Secures Global Identity and Cultural Legacy
  • Home Builders Association of Durham, Orange & Chatham Counties Awards Local Scholarships
  • Artist Séfora Camazano Honored with Prestigious Prize "The New Great Masters in New York"
  • Guests Can Save 20 Percent on a Florida Keys Vacation Home Rental with KeysCaribbean's 'Last-Minute Booking Discount'
  • Home Run Pest & Termite Control Launches Monthly Mosquito Service to Help Wylie, Plano, and Rockwall Homeowners Reclaim Their Backyards
  • Jed the Fish, The Rapscallion of Los Angeles KROQ's Airwaves and Provocateur, Has Signed Off at 69
  • American Mensa Welcomes 7-Year-Old Savannah Boy

Similar on ncarol.com

  • Asset-Backed Green Crypto: Fueling the Trillion-Dollar Revolution
  • NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Ushering in a Disruptive Innovation in Web3
  • Cybersecurity is Protecting Your Personal Information and Your Portfolio
  • The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
  • $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
  • SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
  • Ditch Micromanagement: New Leadership Book for Results-Driven, Accountability-Based Teams
  • Jay Tapp was named Managing Director in British Columbia
  • 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)
  • NASDAQ Uplisting for Higher Market Exposure and Wide Corporate Benefits to AI Boosted Marketing Company On Track Towards $1 Billion Revenue by 2027
Copyright © 2025 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute